3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
2
Neoplasm Metastasis
1
Interventions
Carboplatin
551
Pemetrexed
404
Cisplatin
401
Paclitaxel
273
Docetaxel
255
Gemcitabine
218
pembrolizumab
191
Bevacizumab
190
Erlotinib Hydrochloride
184
Radiotherapy
181
Etoposide
147
durvalumab
140
Nivolumab
134
Drug Therapy
127
osimertinib
107
atezolizumab
92
Gefitinib
74
Radiosurgery
72
anlotinib
69
Vinorelbine
68
tislelizumab
52
Irinotecan
51
Ipilimumab
50
130-nm albumin-bound paclitaxel
50
Taxes
48
Surgical Procedures, Operative
46
Cetuximab
46
sintilimab
45
Albumin-Bound Paclitaxel
45
apatinib
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
L19-IL2 immunocytokine
×
Thoracic
×
Clear all
NCT03705403
2025-01-30
IMMUNOSABR2
Maastricht University Medical Center
Phase 2
Terminated
88 enrolled
NCT02735850
2017-05-23
ImmunoSABR
Maastricht Radiation Oncology
Phase 2
Withdrawn